The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Open accessAbstract
BACKGROUND Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. METHODS AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin <100 μg/L, or 100-299 μg/L with transferrin saturation <20%), and had a left ventricular ejection fraction of less than 50%. Before hospital discharge, participants were randomly assigned (1:1) to receive intravenous ferric carboxymaltose or placebo for up to 24 weeks, dosed according to the extent of iron deficiency. To maintain masking of patients and study personnel, treatments were administered in black syringes by personnel not involved in any study assessments. The primary outcome was a composite of total hospitalisations for heart failure and cardiovascular death up to 52 weeks after randomisation, analysed in all patients who received at least one dose of study treatment and had at least one post-randomisation data point. Secondary outcomes were the composite of total cardiovascular hospitalisations and cardiovascular death; cardiovascular death; total heart failure hospitalisations; time to first heart failure hospitalisation or cardiovascular death; and days lost due to heart failure hospitalisations or cardiovascular death, all evaluated up to 52 weeks after randomisation. Safety was assessed in all patients for whom study treatment was started. A pre-COVID-19 sensitivity analysis on the primary and secondary outcomes was prespecified. This study is registered with ClinicalTrials.gov, NCT02937454, and has now been completed. FINDINGS Between March 21, 2017, and July 30, 2019, 1525 patients were screened, of whom 1132 patients were randomly assigned to study groups. Study treatment was started in 1110 patients, and 1108 (558 in the carboxymaltose group and 550 in the placebo group) had at least one post-randomisation value. 293 primary events (57·2 per 100 patient-years) occurred in the ferric carboxymaltose group and 372 (72·5 per 100 patient-years) occurred in the placebo group (rate ratio [RR] 0·79, 95% CI 0·62-1·01, p=0·059). 370 total cardiovascular hospitalisations and cardiovascular deaths occurred in the ferric carboxymaltose group and 451 occurred in the placebo group (RR 0·80, 95% CI 0·64-1·00, p=0·050). There was no difference in cardiovascular death between the two groups (77 [14%] of 558 in the ferric carboxymaltose group vs 78 [14%] in the placebo group; hazard ratio [HR] 0·96, 95% CI 0·70-1·32, p=0·81). 217 total heart failure hospitalisations occurred in the ferric carboxymaltose group and 294 occurred in the placebo group (RR 0·74; 95% CI 0·58-0·94, p=0·013). The composite of first heart failure hospitalisation or cardiovascular death occurred in 181 (32%) patients in the ferric carboxymaltose group and 209 (38%) in the placebo group (HR 0·80, 95% CI 0·66-0·98, p=0·030). Fewer days were lost due to heart failure hospitalisations and cardiovascular death for patients assigned to ferric carboxymaltose compared with placebo (369 days per 100 patient-years vs 548 days per 100 patient-years; RR 0·67, 95% CI 0·47-0·97, p=0·035). Serious adverse events occurred in 250 (45%) of 559 patients in the ferric carboxymaltose group and 282 (51%) of 551 patients in the placebo group. INTERPRETATION In patients with iron deficiency, a left ventricular ejection fraction of less than 50%, and who were stabilised after an episode of acute heart failure, treatment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations, with no apparent effect on the risk of cardiovascular death. FUNDING Vifor Pharma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
Self-citationIron deficiency in chronic heart failure: an international pooled analysis
Klip, I. T., Comin-Colet, J., Voors, A. A., Ponikowski, P., Enjuanes, C., Banasiak, W., Lok, D. J., Rosentryt, P., Torrens, A., Polonski, L., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.017 · Cited by 736
Iron deficiency: an ominous sign in patients with systolic chronic heart failure
Jankowska, E. A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., Banasiak, W., Polonski, L., Filippatos, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq158 · Cited by 652
Self-citationIron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
Jankowska, E. A., von Haehling, S., Anker, S. D., Macdougall, I. C., & Ponikowski, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs224 · Cited by 399
Hoes, M. F., Grote Beverborg, N., Kijlstra, J. D., Kuipers, J., Swinkels, D. W., Giepmans, B. N. G., Rodenburg, R. J., van Veldhuisen, D. J., de Boer, R. A., & van der Meer, P. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1154 · Cited by 333
Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure
Jankowska, E. A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., von Haehling, S., Doehner, W., Banasiak, W., et al. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.08.003 · Cited by 281
Self-citationRogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., & Yusuf, S. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.29 · Cited by 226
Self-citationSample size calculation for comparing two negative binomial rates
Zhu, H., & Lakkis, H. (2014) · Statistics in Medicine · doi:10.1002/sim.5947 · Cited by 97
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,612
Self-citationPasricha, S.-R., Tye-Din, J., Muckenthaler, M. U., & Swinkels, D. W. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32594-0 · Cited by 1,069
Metadata
- Authors
- Ponikowski, P., Kirwan, B.-A., Anker, S. D., McDonagh, T., Dorobantu, M., Drozdz, J., Fabien, V., Filippatos, G., Göhring, U. M., Keren, A., Khintibidze, I., Kragten, H., Martinez, F. A., Metra, M., Milicic, D., Nicolau, J. C., Ohlsson, M., Parkhomenko, A., Pascual-Figal, D. A., Ruschitzka, F., Sim, D., Skouri, H., van der Meer, P., Lewis, B. S., Comin-Colet, J., von Haehling, S., Cohen-Solal, A., Danchin, N., Doehner, W., Dargie, H. J., Motro, M., Butler, J., Friede, T., Jensen, K. H., Pocock, S., Jankowska, E. A., Azize, G., Fernandez, A., Zapata, G., Garcia Pacho, P., Glenny, A., Ferre Pacora, F., Parody, M., Bono, J., Beltrano, C., Hershson, A., Vita, N., Luquez, H., Cestari, H., Fernandez, H., Prado, A., Berli, M., García Durán, R., Thierer, J., Diez, M., Lobo Marquez, L., Borelli, R., Hominal, M., Metra, M., Ameri, P., Agostoni, P., Salvioni, A., Fattore, L., Gronda, E., Ghio, S., Turrini, F., Uguccioni, M., Di Biase, M., Piepoli, M., Savonitto, S., Mortara, A., Terrosu, P., Fucili, A., Boriani, G., Midi, P., Passamonti, E., Cosmi, F., van der Meer, P., Van Bergen, P., van de Wetering, M., Al-Windy, N., Tanis, W., Meijs, M., Groutars, R., The, H., Kietselaer, B., van Kesteren, H., Beelen, D., Heymeriks, J., Van de Wal, R., Schaap, J., Emans, M., Westendorp, P., Nierop, P., Nijmeijer, R., Manintveld, O., Dorobantu, M., Darabantiu, D., Zdrenghea, D., Toader, D., Petrescu, L., Militaru, C., Crisu, D., Tomescu, M., Stanciulescu, G., Rodica Dan, A., Iosipescu, L., Serban, D., Drozdz, J., Szachniewicz, J., Bronisz, M., Tycińska, A., Wozakowska-Kaplon, B., Mirek-Bryniarska, E., Gruchała, M., Nessler, J., Straburzyńska-Migaj, E., Mizia-Stec, K., Szelemej, R., Gil, R., Gąsior, M., Gotsman, I., Halabi, M., Shochat, M., Shechter, M., Witzling, V, Zukermann, R., Arbel, Y., Flugelman, M., Ben-Gal, T., Zvi, V, Kinany, W., Weinstein, J., Atar, S., Goland, S., Milicic, D., Horvat, D., Tušek, S., Udovicic, M., Šutalo, K., Samodol, A., Pesek, K., Artuković, M., Ružić, A., Šikić, J., McDonagh, T., Trevelyan, J., Wong, Y.-K., Gorog, D., Ray, R., Pettit, S., Sharma, S., Kabir, A., Hamdan, H., Tilling, L., Baracioli, L., Nigro Maia, L., Dutra, O., Reis, G., Pimentel Filho, P., Saraiva, J., Kormann, A., dos Santos, F., Bodanese, L., Almeida, D., Precoma, D., Rassi, S., Costa, F., Kabbani, S., Abdelbaki, K., Abdallah, C., Arnaout, M., Azar, R., Chaaban, S., Raed, O., Kiwan, G., Hassouna, B., Bardaji, A., Zamorano, J., del Prado, S., Gonzalez Juanatey, Jr., Ga Bosa Ojeda, F., Gomez Bueno, M., Molina, B., Pascual Figal, D., Sim, D., Yeo, T., Loh, S., Soon, D., Ohlsson, M., Smith, J., Gerward, S., Khintibidze, I., Lominadze, Z., Chapidze, G., Emukhvari, N., Khabeishvili, G., Chumburidze, V, Paposhvili, K., Shaburishvili, T., Khabeishvili, G., Parhomenko, O., Kraiz, I., Koval, O., Zolotaikina, V, Malynovsky, Y., Vakaliuk, I., Rudenko, L., Tseluyko, V, & Stanislavchuk, M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 396
- Issue
- 10266
- Pages
- 1895-1904
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3106240111
- Cited by
- 795
- References
- 9
- FWCI
- 61.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32339-4
- The paper
- Ponikowski, P., Kirwan, B.-A., Anker, S. D., McDonagh, T., Dorobantu, M., Drozdz, J., Fabien, V., Filippatos, G., Göhring, U. M., Keren, A., Khintibidze, I., Kragten, H., Martinez, F. A., Metra, M., Milicic, D., Nicolau, J. C., Ohlsson, M., Parkhomenko, A., Pascual-Figal, D. A., . . . Stanislavchuk, M. (2020). Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)32339-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.